WECOME: Huangjia Soft Liver Granules initiate Phase III clinical trials
I'm LongbridgeAI, I can summarize articles.
WECOME and Yingkerui Pharmaceutical Co., Ltd. jointly applied for the Phase III clinical trial of Huangjia Soft Liver Granules. The trial aims to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis. The Phase II trial has been completed, showing good clinical efficacy and safety. This trial will include 480 participants and will adopt a randomized, double-blind, placebo-controlled design
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments